Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes

Owing to the increasing prevalence of type 2 diabetes, the development of novel hypoglycemic drugs has become a research hotspot, with the ultimate goal of developing therapeutic drugs that stimulate glucose-induced insulin secretion without inducing hypoglycemia. Vasoactive intestinal peptide (VIP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Xintong, Yang, Dan, Yang, Guimei, Li, Mengnan, Zhang, Jian, Zhang, Jiaxin, Zhang, Yi, Liu, Yunfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531956/
https://www.ncbi.nlm.nih.gov/pubmed/36204104
http://dx.doi.org/10.3389/fendo.2022.984198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531956/
https://www.ncbi.nlm.nih.gov/pubmed/36204104
http://dx.doi.org/10.3389/fendo.2022.984198

Ejemplares similares